

Christopher J Rhodes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4771251/publications.pdf>

Version: 2024-02-01

48
papers

2,678
citations

257357

24
h-index

265120

42
g-index

51
all docs

51
docs citations

51
times ranked

3595
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. <i>Nature Communications</i> , 2018, 9, 1416. | 5.8 | 279 |
| 2 | Iron Deficiency and Raised Hepcidin in Idiopathic Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2011, 58, 300-309. | 1.2 | 208 |
| 3 | In Pulmonary Arterial Hypertension, Reduced BMPR2 Promotes Endothelial-to-Mesenchymal Transition via HMGA1 and Its Target Slug. <i>Circulation</i> , 2016, 133, 1783-1794. | 1.6 | 183 |
| 4 | Machine Learning of Three-dimensional Right Ventricular Motion Enables Outcome Prediction in Pulmonary Hypertension: A Cardiac MR Imaging Study. <i>Radiology</i> , 2017, 283, 381-390. | 3.6 | 161 |
| 5 | Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. <i>Heart</i> , 2011, 97, 1054-1060. | 1.2 | 154 |
| 6 | Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension. <i>Circulation</i> , 2017, 135, 460-475. | 1.6 | 154 |
| 7 | Reduced MicroRNA-150 Is Associated with Poor Survival in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 294-302. | 2.5 | 153 |
| 8 | Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. <i>Lancet Respiratory Medicine</i> , 2019, 7, 227-238. | 5.2 | 122 |
| 9 | Phenotypic Characterization of <i>EIF2AK4</i> Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. <i>Circulation</i> , 2017, 136, 2022-2033. | 1.6 | 111 |
| 10 | Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. <i>Lancet Respiratory Medicine</i> , 2017, 5, 717-726. | 5.2 | 99 |
| 11 | Therapeutic targets in pulmonary arterial hypertension. <i>Circulation</i> , 2009, 121, 69-88. | | 80 |
| 12 | Characterization of <i>GDF2</i> Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 575-585. | 2.5 | 80 |
| 13 | Human PAH is characterized by a pattern of lipid-related insulin resistance. <i>JCI Insight</i> , 2019, 4, . | 2.3 | 69 |
| 14 | Aberrant Chloride Intracellular Channel 4 Expression Contributes to Endothelial Dysfunction in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2014, 129, 1770-1780. | 1.6 | 63 |
| 15 | Immunoglobulin-driven Complement Activation Regulates Proinflammatory Remodeling in Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 224-239. | 2.5 | 60 |
| 16 | Therapeutic potential of KLF2-induced exosomal microRNAs in pulmonary hypertension. <i>Nature Communications</i> , 2020, 11, 1185. | 5.8 | 52 |
| 17 | <i>miR-21</i> /DDAH1 pathway regulates pulmonary vascular responses to hypoxia. <i>Biochemical Journal</i> , 2014, 462, 103-112. | 1.7 | 45 |
| 18 | Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 586-594. | 2.5 | 45 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Codependence of Bone Morphogenetic Protein Receptor 2 and Transforming Growth Factor- β 2 in Elastic Fiber Assembly and Its Perturbation in Pulmonary Arterial Hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1559-1569. | 1.1 | 41 |
| 20 | Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future. , 2016, 164, 195-203. | | 37 |
| 21 | Using the Plasma Proteome for Risk Stratifying Patients with Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1102-1111. | 2.5 | 35 |
| 22 | Reduced plasma levels of small HDL particles transporting fibrinolytic proteins in pulmonary arterial hypertension. <i>Thorax</i> , 2019, 74, 380-389. | 2.7 | 34 |
| 23 | The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1801805. | 3.1 | 31 |
| 24 | Traffic exposures, air pollution and outcomes in pulmonary arterial hypertension: a UK cohort study analysis. <i>European Respiratory Journal</i> , 2019, 53, 1801429. | 3.1 | 31 |
| 25 | A diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach. <i>EBioMedicine</i> , 2021, 69, 103444. | 2.7 | 30 |
| 26 | Bayesian Inference Associates Rare <i>KDR</i> Variants With Specific Phenotypes in Pulmonary Arterial Hypertension. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, . | 1.6 | 29 |
| 27 | Supplementation with Iron in Pulmonary Arterial Hypertension. Two Randomized Crossover Trials. <i>Annals of the American Thoracic Society</i> , 2021, 18, 981-988. | 1.5 | 28 |
| 28 | Recent advances in pulmonary arterial hypertension. <i>F1000Research</i> , 2018, 7, 1128. | 0.8 | 27 |
| 29 | Mendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2020, 55, 1901486. | 3.1 | 26 |
| 30 | Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2021, 57, 2003201. | 3.1 | 25 |
| 31 | \pm 1-A680T Variant in GUCY1A3 as a Candidate Conferring Protection From Pulmonary Hypertension Among Kyrgyz Highlanders. <i>Circulation: Cardiovascular Genetics</i> , 2014, 7, 920-929. | 5.1 | 23 |
| 32 | Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. <i>Nature Communications</i> , 2021, 12, 7104. | 5.8 | 21 |
| 33 | Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1449-1460. | 2.5 | 19 |
| 34 | Harnessing Big Data to Advance Treatment and Understanding of Pulmonary Hypertension. <i>Circulation Research</i> , 2022, 130, 1423-1444. | 2.0 | 19 |
| 35 | The application of "omics" to pulmonary arterial hypertension. <i>British Journal of Pharmacology</i> , 2021, 178, 108-120. | 2.7 | 18 |
| 36 | Severe Pulmonary Arterial Hypertension Is Characterized by Increased Neutrophil Elastase and Relative Elafin Deficiency. <i>Chest</i> , 2021, 160, 1442-1458. | 0.4 | 17 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | The pathophysiological role of novel pulmonary arterial hypertension gene <i>SOX17</i> . <i>European Respiratory Journal</i> , 2021, 58, 2004172. | 3.1 | 16 |
| 38 | Metabolic pathways associated with right ventricular adaptation to pulmonary hypertension: 3D analysis of cardiac magnetic resonance imaging. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 668-676. | 0.5 | 13 |
| 39 | NHLBI-CMREF Workshop Report on Pulmonary Vascular Disease Classification. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2040-2052. | 1.2 | 13 |
| 40 | Autoimmunity Is a Significant Feature of Idiopathic Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 81-93. | 2.5 | 9 |
| 41 | Pulmonary Hypertension: Biomarkers. <i>Handbook of Experimental Pharmacology</i> , 2013, 218, 77-103. | 0.9 | 5 |
| 42 | Expression Quantitative Trait Locus Mapping in Pulmonary Arterial Hypertension. <i>Genes</i> , 2020, 11, 1247. | 1.0 | 3 |
| 43 | Metabolomic Insights in Pulmonary Arterial Hypertension. <i>Advances in Pulmonary Hypertension</i> , 2018, 17, 103-109. | 0.1 | 2 |
| 44 | Plasma metabolomics in chronic thromboembolic pulmonary hypertension. , 2020, , . | | 1 |
| 45 | Targeting Vessel Formation in Pulmonary Arterial Hypertension: Is the Endostatin/Thrombospondin 1 Pathway a New Hope?. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2020, 62, 411-412. | 1.4 | 0 |
| 46 | Pathobiology of Pulmonary Hypertension. , 2022, , 530-541. | | 0 |
| 47 | Blood biomarkers. , 2011, , 146-158. | | 0 |
| 48 | Multi-omic profiling in pulmonary arterial hypertension. , 2020, , . | | 0 |